In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma

Extensive inter-individual variation in response to chemotherapy (sensitive vs resistant tumors) is a serious cause of concern in the treatment of multiple myeloma (MM). In this study, we used human myeloma cell lines (HMCLs), and patient-derived CD138+ cells to compare kinetic changes in gene expre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2020-07, Vol.10 (7), p.78-78, Article 78
Hauptverfasser:	Mitra, Amit Kumar, Kumar, Harish, Ramakrishnan, Vijay, Chen, Li, Baughn, Linda, Kumar, Shaji, Rajkumar, S. Vincent, Van Ness, Brian G.
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1990/804 631/67/69 631/67/70 Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biomarkers, Tumor Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell adhesion & migration Chemotherapy Computational Biology Data analysis Drug dosages Drug Resistance, Neoplasm - genetics Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Genomics Heat shock proteins Heat-Shock Proteins - genetics Hematology Humans Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - pathology Oncology Patients Prognosis Proteasome Inhibitors - pharmacology Proteasome Inhibitors - therapeutic use Software Transcriptome Unfolded Protein Response - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Extensive inter-individual variation in response to chemotherapy (sensitive vs resistant tumors) is a serious cause of concern in the treatment of multiple myeloma (MM). In this study, we used human myeloma cell lines (HMCLs), and patient-derived CD138+ cells to compare kinetic changes in gene expression patterns between innate proteasome inhibitor (PI)-sensitive and PI-resistant HMCLs following test dosing with the second-generation PI Ixazomib. We found 1553 genes that changed significantly post treatment in PI-sensitive HMCLs compared with only seven in PI-resistant HMCLs ( p
ISSN:	2044-5385 2044-5385
DOI:	10.1038/s41408-020-00344-9